Everett E. Vokes
The University of Texas MD Anderson Cancer Center
3 papers in the Anchorcite directory, published between 2015 and 2016, cited 23,218 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
- Head and Neck Cancer Studies · 1 paper
- Nonmelanoma Skin Cancer Studies · 1 paper
Frequent co-authors
- Luis G Paz-Ares · 2 papers
- David Robert Spigel · 2 papers
- Martin B. Steins · 2 papers
- Neal Ready · 2 papers
- Esther Holgado · 2 papers
- Jérôme Fayette · 2 papers
- Elena V Poddubskaya · 2 papers
- George R. Blumenschein · 2 papers
Papers
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 8,551 citations
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4…
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine · 2016 · 5,194 citations
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.…
Metadata from OpenAlex (CC0).